ProCE Banner Activity

Phase Ib Study: Venetoclax/Azacitidine in Treatment-Naive Higher-Risk MDS

Slideset Download
Conference Coverage
In this phase Ib study in previously untreated higher-risk MDS, venetoclax plus azacitidine was safe and appeared to induce rapid, durable responses and a high remission rate, with molecular responses observed across key mutational profiles.

Released: December 15, 2021

Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo Inc

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp

Novartis Pharmaceuticals Corporation